Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SOLID BIOSCIENCES INC.

(SLDB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
1.75(c) 1.7(c) 1.77(c) 1.69(c) 1.76(c) Last
2 742 603 1 601 185 3 419 794 2 987 448 3 401 974 Volume
-3.85% -2.86% +4.12% -4.52% +4.14% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 12,7 M - -
Net income 2021 -76,1 M - -
Net cash position 2021 83,7 M - -
P/E ratio 2021 -2,46x
Yield 2021 -
Sales 2022 9,46 M - -
Net income 2022 -99,8 M - -
Net cash position 2022 225 M - -
P/E ratio 2022 -2,28x
Yield 2022 -
Capitalization 194 M 194 M -
EV / Sales 2021 8,68x
EV / Sales 2022 -3,21x
Nbr of Employees 70
Free-Float 75,1%
More Financials
Company
Solid Biosciences Inc. is a life science company. The Company is focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Its lead program, SGT-001, is a gene transfer candidate under investigation for its ability to drive functional dystrophin protein expression in patientÔÇÖs muscles and improve the course of the disease. SGT-001 is designed to address the underlying... 
More about the company
Ratings of Solid Biosciences Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about SOLID BIOSCIENCES INC.
11/03LETTER TO THE DUCHENNE COMMUNITY : IGNITE DMD Phase I/II Clinical Trial and Pipeline Updat..
PU
11/03Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results
GL
11/03SOLID BIOSCIENCES INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/03Solid Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/02Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therap..
AQ
10/21SOLID BIOSCIENCES : to Participate at the Jefferies Gene Therapy/Editing Summit
GL
10/04SOLID BIOSCIENCES : Forge Biologics Team Up to Develop Gene Therapy for Muscular Dystrophy
MT
10/04SOLID BIOSCIENCES : and Forge Biologics Announce Viral Vector Contract Development and cGM..
BU
10/04Solid Biosciences and Forge Biologics Announces Viral Vector Contract Development and c..
CI
09/29SOLID BIOSCIENCES : Reports Additional Pulmonary Function Data From Phase 1/2 Clinical Tri..
MT
09/29SOLID BIOSCIENCES INC. : Other Events (form 8-K)
AQ
09/29SOLID BIOSCIENCES : Reports Additional Pulmonary Function Results from the Ongoing IGNITE ..
AQ
09/29Solid Biosciences Inc. Reports Additional Positive Pulmonary Function Data from the Fir..
CI
09/27SOLID BIOSCIENCES : Other Events (form 8-K/A)
AQ
09/24SOLID BIOSCIENCES : Chardan Adjusts Price Target on Solid Biosciences to $17 From $20, Mai..
MT
More news
News in other languages on SOLID BIOSCIENCES INC.
10/05SOLID BIOSCIENCES : und Forge Biologics geben eine Vertragsentwicklung für virale Vektoren..
10/05SOLID BIOSCIENCES : et Forge Biologics annoncent un partenariat de développement et fabric..
10/04Solid Biosciences et Forge Biologics s'associent pour développer une thérapie génique c..
09/29Solid Biosciences présente des données supplémentaires sur la fonction pulmonaire dans ..
05/14MISE À JOUR SECTORIELLE : Les actions du secteur de la santé augmentent vendredi mais sont..
More news
Analyst Recommendations on SOLID BIOSCIENCES INC.
More recommendations
Chart SOLID BIOSCIENCES INC.
Duration : Period :
Solid Biosciences Inc. Technical Analysis Chart | SLDB | US83422E1055 | MarketScreener
Technical analysis trends SOLID BIOSCIENCES INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 1,76 $
Average target price 8,50 $
Spread / Average Target 383%
EPS Revisions
Managers and Directors
Ilan Ganot President, Chief Executive Officer & Director
Stephen J. DiPalma Chief Financial Officer & Treasurer
Ian Frederick Smith Chairman
Carl Morris Chief Scientific Officer
Cathryn M. Clary Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SOLID BIOSCIENCES INC.-76.78%194
GILEAD SCIENCES, INC.19.29%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.78%63 017
VERTEX PHARMACEUTICALS-13.24%52 137